Amifostine
- Generic Name
- Amifostine
- Brand Names
- Ethyol
- Drug Type
- Small Molecule
- Chemical Formula
- C5H15N2O3PS
- CAS Number
- 20537-88-6
- Unique Ingredient Identifier
- ILA426L95O
- Background
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
- Indication
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
- Associated Conditions
- Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLeukemia
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
- Conditions
- Drug/Agent Toxicity by Tissue/OrganHead and Neck CancerOral ComplicationsRadiation Toxicity
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 5
- Registration Number
- NCT00025298
- Locations
- 🇮🇹
Ospedale Santa Croce, Cuneo, Italy
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
- Conditions
- Cervical CancerRadiation Toxicity
- Interventions
- Radiation: External beam radiation therapyRadiation: Intracavitary brachytherapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT00012012
- Locations
- 🇺🇸
Cancer Treatment Center, Wooster, Ohio, United States
🇺🇸Akron City Hospital, Akron, Ohio, United States
🇺🇸Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmDrug/Agent Toxicity by Tissue/Organ
- Interventions
- Biological: filgrastimProcedure: bone marrow ablation with stem cell supportProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 8
- Registration Number
- NCT00052884
- Locations
- 🇺🇸
Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiation: Radiation therapy
- First Posted Date
- 2002-06-26
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00040365
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia
- Conditions
- Fanconi's Anemia
- First Posted Date
- 2000-08-04
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00006127
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.